期刊文献+

晚期卵巢癌化学治疗的新进展 被引量:2

下载PDF
导出
摘要 多数卵巢癌患者就诊时即为晚期,故死亡率较高。化疗是晚期卵巢癌的主要治疗方法之一。紫杉醇/顺铂或卡铂静脉化疗已成为晚期卵巢癌一线治疗方案,使其疗效及预后有一定程度改善。腹腔化疗、淋巴管灌注化疗、动脉化疗及高剂量化疗等的临床研究进展,为晚期卵巢癌治疗提供多种途径。
出处 《国外医学(妇产科学分册)》 2003年第5期322-325,共4页 Foreign Medical Sciences(Obstet Gynecol Fascicle)
  • 相关文献

参考文献20

  • 1de Jongh FE, van Veen RN, Veltman S J, et al. Weekly high-dose cisplatin is a feasible treament option: analysis on prognotic factors for toxicity in 400 patients. BJC, 2003, 88(8):1199-1206.
  • 2Eltabbakh GH, Piver MS, Hempling RE, et al. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol, 1998, 7(2):190-195.
  • 3Umesaki N, Tanaka T, Muso H, et al. Intermittent cisplatin therapy for stage Ⅲ ovarian cancer patients following clinical remission. Gynecol Obstet Invest, 1999, 47{2):139-143.
  • 4Piccart MJ, Green JA, Lacave AJ,et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancerA randomized phase Ⅱ study of the European Organization for Researchand Treatment of Cancer Gynecology Group. J Clin Oncol, 2000, 18(6):1193-1202.
  • 5Piccart M J, Bertelsen K, James K, et al .Bandomized intergroup trial of cisplatin-paelitaxel versus cisplatin-cyclophosphamide in woman with advanced epithelial ovarian cancer. J Natl Cancer Inst, 2000, 92(9): 699-708.
  • 6Neijt JP, Engelholm SA, Tuxen MIL et al. Exploratory phase Ⅲ study of paclitaxel and cisplatin venus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol, 2000, 18(17):3084-3092.
  • 7Yamamoto R, Minobe S, Kaneuchi M, et al. A phase Ⅰ/Ⅱ study of carboplatin and paclitaxel in patients with epithelial ovarian cancer. Jpn J Clin Oncol,2002, 32(4):128-134.
  • 8Covens A, Carey M, Bryson P, et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage Ⅱ,Ⅲ, or Ⅳ epithelial ovarian cancer. Gynecol Oncol, 2002,85(1):71-80.
  • 9Papadimitriou CA, Moulopoulos LA,Vlahos G, et al. Paclitaxel,cisplatin,and epirubicin first-line chemotherapy in stage Ⅲ and Ⅳ ovarian carcinoma long-term results of a phase Ⅱ study. Cancer,2000, 89(7):1547-1554.
  • 10Kaye SB, Scottish Gynaecological Cancer Trials Group. The integration of docetaxel into flint-line chemotherapy for ovarian cancer. Int J Gynecol Cancer, 2001, 11 [Suppl 1]:31-33.

同被引文献11

  • 1王建.紫杉醇联合顺铂治疗晚期卵巢癌30例[J].肿瘤防治杂志,2004,11(11):1228-1228. 被引量:2
  • 2任婕,赵厚育.紫杉醇、顺铂联合化疗在晚期卵巢上皮性癌的应用[J].实用妇产科杂志,2005,21(5):293-294. 被引量:4
  • 3Mliedzinska maciejewska M, Wcislo G. Mechanism of multidrug resistance of ovarian cancer[J]. Prxegl Lek, 2002,59: 854-858.
  • 4Piccart M J, Bertelsen K,Jamas K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cispiantin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year resuits[J]. J Natl Cancer Inst, 2000,92(9):699-708.
  • 5Ansquer Y, Le Blanc E. Clough K,et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study[J]. Cancer,2001,91(12):2329-2334.
  • 6Mliedzinska maciejewska M, Wciso G. Mechanism of multidrug resistance of ovarian cancer[ J ]. Prxegl Lek ,2002,59 (2) : 854 - 858.
  • 7Piccart M J, Bertesen K, Jamas K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cispiantin-cyclophospharnide in women with advanced epithelial ovarian cancer:three-year results[ J]. J Natl Cancer Inst,2000,92 (9) :699 - 708.
  • 8Ansquer Y, Le-blanc E, Clough K, et al. Neoadjuvant chemotherapy for unrespectable ovarian earcinoma:a French multicenter study [ J ]. Canc- er,2001,91 (12) :2329 -2334.
  • 9Goldberg JM, Piver MS, Hemplong RE, et al. Paditaxel and cisolatin combination chemotherapy in recarrent epithclial ovariar cancer[ J]. Gy- necol Oncol, 1996,63 ( 3 ) : 312 - 317.
  • 10徐秀萍,张菊,施秀梅.卵巢癌患者运用紫杉醇联合顺铂化疗的护理[J].当代护士(中旬刊),2010,17(12):37-38. 被引量:3

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部